Ropes & Gray represented AvenCell Therapeutics in its $112 million Series B funding round led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads VenturesJapan, Piper Heartland Healthcare Capital and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences.
AvenCell is a leading clinical-stage cell therapy company. The new funding will accelerate clinical validation of AvenCell's proprietary Universal Switchable CAR-T cell therapy platform, for the treatment of a wide range of hematologic malignancies and auto-immune diseases.
The deal team was led by venture capital & emerging companies partner Rajarshi Banerjee and life sciences partner Michael Beauvais, and included litigation & enforcement partner Lisa Kaltenbrunner and finance partner Milap Patel.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.